Wall Street analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce earnings of ($0.30) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.23). CymaBay Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would suggest a negative year over year growth rate of 42.9%. The business is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.26) to ($1.01). For the next financial year, analysts anticipate that the firm will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.46) to ($0.46). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.04).

A number of equities analysts have recently commented on CBAY shares. BidaskClub lowered shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 31st. Raymond James started coverage on shares of CymaBay Therapeutics in a report on Thursday, June 28th. They issued an “outperform” rating and a $20.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $23.00 price target (up previously from $21.00) on shares of CymaBay Therapeutics in a report on Wednesday, June 6th. Zacks Investment Research lowered shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. CymaBay Therapeutics currently has an average rating of “Buy” and an average target price of $21.88.

Shares of NASDAQ:CBAY traded down $0.68 during trading on Tuesday, reaching $11.39. The company had a trading volume of 1,297,666 shares, compared to its average volume of 390,113. The firm has a market capitalization of $672.61 million, a price-to-earnings ratio of -14.42 and a beta of 1.98. CymaBay Therapeutics has a 12 month low of $7.36 and a 12 month high of $15.59.

In related news, VP Daniel Menold sold 5,000 shares of the stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $13.00, for a total transaction of $65,000.00. Following the transaction, the vice president now owns 5,000 shares of the company’s stock, valued at approximately $65,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in CBAY. Hillsdale Investment Management Inc. bought a new position in shares of CymaBay Therapeutics during the 1st quarter valued at $104,000. LPL Financial LLC purchased a new stake in CymaBay Therapeutics during the 1st quarter valued at $130,000. Legal & General Group Plc purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $134,000. State Board of Administration of Florida Retirement System purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $145,000. Finally, Teacher Retirement System of Texas purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $151,000. 95.44% of the stock is currently owned by institutional investors.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Recommended Story: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.